Bactericidal and virucidal pharmaceutical composition

Abstract

A bactericidal and virucidal pharmaceutical composition for use on epithelial tissues such as pulmonary, nasal and oral tissues, which comprises a non-steroidal anti-inflammatory drug (NSAID) in a concentration between 5 and 500 mM and a salt, being the NSAID preferably solubilized in a hypertonic saline solution applicable in therapies for viral infections of the Herpes simplex type. The composition can be used in therapies for herpes simplex viral infections, be used as a bactericidal mouthwash, or be vehiculated to the lung by using a nebuliser, for cystic fibrosis.

What is claimed is: 
     
       1. A method for treating a patient with cystic fibrosis, comprising administering by inhalation a nebulized pharmaceutical composition, wherein the pharmaceutical composition comprises ibuprofen or a pharmaceutically acceptable salt thereof in a concentration from 5 to 100 mM solubilized in a hypertonic saline solution comprising between 0.3 M and 2 M sodium chloride. 
     
     
       2. The method of  claim 1 , wherein the concentration of ibuprofen or a pharmaceutically acceptable salt thereof in the hypertonic saline solution is from 5 to 80 mM. 
     
     
       3. The method of  claim 2 , wherein the concentration of sodium chloride in the hypertonic saline solution is between 0.4 and 1.0 Molar. 
     
     
       4. The method of  claim 3 , wherein the pH of the hypertonic saline solution is between 6.0 and 8.5. 
     
     
       5. The method of  claim 3 , wherein said pharmaceutical composition comprises a pharmaceutically acceptable salt of ibuprofen selected from the sodium salt of ibuprofen, the potassium salt of ibuprofen, the lithium salt of ibuprofen and a combination thereof. 
     
     
       6. The method of  claim 3 , wherein the pharmaceutical composition comprises the sodium salt of ibuprofen. 
     
     
       7. The method of  claim 1 , wherein the concentration of ibuprofen or a pharmaceutically acceptable salt thereof in the hypertonic saline solution is from 5 to 50 mM. 
     
     
       8. The method of  claim 7 , wherein the concentration of sodium chloride in the hypertonic saline solution is between 0.4 and 1.0 Molar. 
     
     
       9. The method of  claim 8 , wherein the pH of the hypertonic saline solution is between 6.0 and 8.5. 
     
     
       10. The method of  claim 8 , wherein said pharmaceutical composition comprises a pharmaceutically acceptable salt of ibuprofen selected from the sodium salt of ibuprofen, the potassium salt of ibuprofen, the lithium salt of ibuprofen and a combination thereof. 
     
     
       11. The method of  claim 8 , wherein the pharmaceutical composition comprises the sodium salt of ibuprofen. 
     
     
       12. The method of  claim 1 , wherein the concentration of ibuprofen or a pharmaceutically acceptable salt thereof in the hypertonic saline solution is 50 mM. 
     
     
       13. The method of  claim 1 , wherein the concentration of sodium chloride in the hypertonic saline solution is between 0.4 and 1.0 Molar. 
     
     
       14. The method of  claim 13 , wherein the pH of the hypertonic saline solution is between 6.0 and 8.5. 
     
     
       15. The method of  claim 13 , wherein said pharmaceutical composition comprises a pharmaceutically acceptable salt of ibuprofen selected from the sodium salt of ibuprofen, the potassium salt of ibuprofen, the lithium salt of ibuprofen and a combination thereof. 
     
     
       16. The method of  claim 13 , wherein the pharmaceutical composition comprises the sodium salt of ibuprofen. 
     
     
       17. The method of  claim 1 , wherein the patient is not being treated with antibiotics.